Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (AMRX): 130 pipeline candidates · 3 upcoming catalysts · ~77 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
76.6 months
N/A
Lead: Approved
130 candidates
3 upcoming, next in ~196d
0 buys · 1 sell (180d)
A transparent, data-derived signal for Amneal Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.2B
Cash
$204.4M
Quarterly Burn
$26.7M
Runway
76.6 mo
Revenue
$722.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (130 candidates)
| Drug | Phase |
|---|---|
| 18F-NOTA-ABY-030 | Phase 1 |
| Adagrasib | Phase 2 |
| alymsys | Approved |
| Amivantamab | Phase 3 |
| Amivantamab and Recombinant Human Hyaluronidase | Phase 3 |
| atropine | Approved |
| azacitidine | Approved |
| azelastine | Approved |
| BET Bromodomain Inhibitor ZEN-3694 | Phase 1 |
| bexarotene | Approved |
Showing 10 of 130 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Frequently asked questions
How many drug candidates are in Amneal Pharmaceuticals, Inc.'s pipeline?
Amneal Pharmaceuticals, Inc. (AMRX) has 130 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Amneal Pharmaceuticals, Inc.'s lead drug candidate?
Amneal Pharmaceuticals, Inc.'s most advanced tracked candidate is 18F-NOTA-ABY-030 (Phase 1) for SCC - Squamous Cell Carcinoma.
What is Amneal Pharmaceuticals, Inc.'s next catalyst?
Amneal Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (" — expected December 31, 2026.
What is Amneal Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Amneal Pharmaceuticals, Inc. has approximately 76.6 months of cash runway.
What is Amneal Pharmaceuticals, Inc.'s market capitalization?
Amneal Pharmaceuticals, Inc.'s market capitalization is approximately $5.2B.
Get the full picture on Amneal Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.